Free Trial

DaVita (DVA) Competitors

DaVita logo
$174.81 +0.25 (+0.15%)
Closing price 11/13/2026 03:59 PM Eastern
Extended Trading
$174.50 -0.31 (-0.18%)
As of 11/13/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

Should you buy DaVita stock or one of its competitors? DaVita's main competitors and comparable companies include Align Technology (ALGN), DexCom (DXCM), HealthEquity (HQY), Merit Medical Systems (MMSI), and Cardinal Health (CAH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does DaVita compare to Align Technology?

DaVita (NYSE:DVA) and Align Technology (NASDAQ:ALGN) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

In the previous week, DaVita had 5 more articles in the media than Align Technology. MarketBeat recorded 15 mentions for DaVita and 10 mentions for Align Technology. Align Technology's average media sentiment score of 1.46 beat DaVita's score of 0.53 indicating that Align Technology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DaVita
4 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Align Technology
7 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$14.17B0.78$746.80M$13.5812.87
Align Technology$4.03B2.94$410.35M$6.8724.50

DaVita presently has a consensus price target of $235.86, indicating a potential upside of 34.92%. Align Technology has a consensus price target of $193.08, indicating a potential upside of 14.71%. Given DaVita's stronger consensus rating and higher possible upside, analysts clearly believe DaVita is more favorable than Align Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DaVita
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
Align Technology
1 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.53

90.1% of DaVita shares are owned by institutional investors. Comparatively, 88.4% of Align Technology shares are owned by institutional investors. 1.9% of DaVita shares are owned by company insiders. Comparatively, 0.8% of Align Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Align Technology has a net margin of 11.83% compared to DaVita's net margin of 6.49%. Align Technology's return on equity of 15.96% beat DaVita's return on equity.

Company Net Margins Return on Equity Return on Assets
DaVita6.49% -225.93% 5.42%
Align Technology 11.83%15.96%10.48%

DaVita has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Align Technology has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market.

Summary

Align Technology beats DaVita on 9 of the 17 factors compared between the two stocks.

How does DaVita compare to DexCom?

DaVita (NYSE:DVA) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, DaVita had 7 more articles in the media than DexCom. MarketBeat recorded 15 mentions for DaVita and 8 mentions for DexCom. DexCom's average media sentiment score of 0.96 beat DaVita's score of 0.53 indicating that DexCom is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DaVita
4 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
DexCom
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DexCom has lower revenue, but higher earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$14.17B0.78$746.80M$13.5812.87
DexCom$4.66B6.67$836.30M$2.5532.68

DaVita currently has a consensus price target of $235.86, suggesting a potential upside of 34.92%. DexCom has a consensus price target of $95.50, suggesting a potential upside of 14.60%. Given DaVita's higher possible upside, research analysts clearly believe DaVita is more favorable than DexCom.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DaVita
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
DexCom
0 Sell rating(s)
2 Hold rating(s)
24 Buy rating(s)
2 Strong Buy rating(s)
3.00

DexCom has a net margin of 19.42% compared to DaVita's net margin of 6.49%. DexCom's return on equity of 37.77% beat DaVita's return on equity.

Company Net Margins Return on Equity Return on Assets
DaVita6.49% -225.93% 5.42%
DexCom 19.42%37.77%15.98%

90.1% of DaVita shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 1.9% of DaVita shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DaVita has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Summary

DexCom beats DaVita on 12 of the 17 factors compared between the two stocks.

How does DaVita compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and DaVita (NYSE:DVA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

HealthEquity has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, DaVita has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

HealthEquity has a net margin of 17.36% compared to DaVita's net margin of 6.49%. HealthEquity's return on equity of 15.33% beat DaVita's return on equity.

Company Net Margins Return on Equity Return on Assets
HealthEquity17.36% 15.33% 9.51%
DaVita 6.49%-225.93%5.42%

DaVita has higher revenue and earnings than HealthEquity. DaVita is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HealthEquity$1.36B6.28$215.20M$2.7737.35
DaVita$14.17B0.78$746.80M$13.5812.87

HealthEquity currently has a consensus price target of $113.53, indicating a potential upside of 9.74%. DaVita has a consensus price target of $235.86, indicating a potential upside of 34.92%. Given DaVita's higher probable upside, analysts clearly believe DaVita is more favorable than HealthEquity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HealthEquity
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92
DaVita
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

In the previous week, DaVita had 13 more articles in the media than HealthEquity. MarketBeat recorded 15 mentions for DaVita and 2 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.63 beat DaVita's score of 0.53 indicating that HealthEquity is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HealthEquity
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
DaVita
4 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

99.6% of HealthEquity shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 1.6% of HealthEquity shares are owned by insiders. Comparatively, 1.9% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

HealthEquity beats DaVita on 10 of the 17 factors compared between the two stocks.

How does DaVita compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and DaVita (NYSE:DVA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

99.7% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 0.7% of Merit Medical Systems shares are owned by insiders. Comparatively, 1.9% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Merit Medical Systems has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, DaVita has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

In the previous week, DaVita had 12 more articles in the media than Merit Medical Systems. MarketBeat recorded 15 mentions for DaVita and 3 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 0.96 beat DaVita's score of 0.53 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merit Medical Systems
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
DaVita
4 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Merit Medical Systems currently has a consensus target price of $105.55, indicating a potential upside of 21.83%. DaVita has a consensus target price of $235.86, indicating a potential upside of 34.92%. Given DaVita's higher possible upside, analysts clearly believe DaVita is more favorable than Merit Medical Systems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merit Medical Systems
0 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.62
DaVita
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

DaVita has higher revenue and earnings than Merit Medical Systems. DaVita is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$1.52B3.42$128.49M$2.6632.57
DaVita$14.17B0.78$746.80M$13.5812.87

Merit Medical Systems has a net margin of 9.94% compared to DaVita's net margin of 6.49%. Merit Medical Systems' return on equity of 14.12% beat DaVita's return on equity.

Company Net Margins Return on Equity Return on Assets
Merit Medical Systems9.94% 14.12% 8.37%
DaVita 6.49%-225.93%5.42%

Summary

Merit Medical Systems beats DaVita on 9 of the 16 factors compared between the two stocks.

How does DaVita compare to Cardinal Health?

Cardinal Health (NYSE:CAH) and DaVita (NYSE:DVA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Cardinal Health had 8 more articles in the media than DaVita. MarketBeat recorded 23 mentions for Cardinal Health and 15 mentions for DaVita. Cardinal Health's average media sentiment score of 0.83 beat DaVita's score of 0.53 indicating that Cardinal Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardinal Health
10 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DaVita
4 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Cardinal Health has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardinal Health$254.25B0.26$1.71B$7.7336.42
DaVita$14.17B0.78$746.80M$13.5812.87

Cardinal Health has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, DaVita has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

DaVita has a net margin of 6.49% compared to Cardinal Health's net margin of 0.71%. Cardinal Health's return on equity of -102.72% beat DaVita's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardinal Health0.71% -102.72% 4.86%
DaVita 6.49%-225.93%5.42%

Cardinal Health currently has a consensus price target of $279.44, indicating a potential downside of 0.75%. DaVita has a consensus price target of $235.86, indicating a potential upside of 34.92%. Given DaVita's higher probable upside, analysts clearly believe DaVita is more favorable than Cardinal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardinal Health
0 Sell rating(s)
3 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.89
DaVita
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

87.2% of Cardinal Health shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 0.1% of Cardinal Health shares are owned by insiders. Comparatively, 1.9% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Cardinal Health beats DaVita on 9 of the 17 factors compared between the two stocks.

Get DaVita News Delivered to You Automatically

Sign up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DVA vs. The Competition

MetricDaVitaHealthcare Providers & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$11.00B$10.86B$7.89B$23.55B
Dividend YieldN/A2.54%2.47%3.78%
P/E Ratio12.8736.2734.5929.83
Price / Sales0.782.108.663.20
Price / Cash8.0423.2821.0215.64
Price / Book-33.053.994.804.11
Net Income$746.80M$335.01M$3.52B$1.08B
7 Day Performance-5.77%-2.55%-3.20%-1.58%
1 Month Performance-6.60%0.01%-1.47%0.28%
1 Year Performance43.82%21.17%1.46%7.30%

DaVita Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DVA
DaVita
4.3981 of 5 stars
$174.81
+0.1%
$235.86
+34.9%
+43.8%$11.00B$14.17B12.8778,000
ALGN
Align Technology
3.8558 of 5 stars
$174.26
+5.0%
$193.08
+10.8%
+22.7%$11.81B$4.03B17.6720,290
DXCM
DexCom
3.6496 of 5 stars
$81.07
+2.1%
$95.50
+17.8%
+43.5%$33.00B$4.66B33.1411,000
HQY
HealthEquity
3.7794 of 5 stars
$102.11
-1.5%
$113.53
+11.2%
+1.7%$9.00B$1.31B36.862,814
MMSI
Merit Medical Systems
3.5811 of 5 stars
$88.42
+1.4%
$105.55
+19.4%
+1.8%$5.43B$1.52B33.247,500

Related Companies and Tools


This page (NYSE:DVA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners